Nuvation Bio to Present at the Cantor Global Healthcare Conference
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage biopharmaceutical company focusing on oncology, has announced its participation in the Cantor Global Healthcare Conference. The event is scheduled for Thursday, September 19, 2024, at 9:45 a.m. E.T. in New York, NY.
Dr. David Hung, the Founder, President, and Chief Executive Officer of Nuvation Bio, will be presenting at the conference. Interested parties can access a live webcast of the presentation through the company's investor relations website. For those unable to attend live, an archived recording will be available for 90 days following the event.
Nuvation Bio Inc. (NYSE: NUVB), un'azienda biofarmaceutica in fase clinica avanzata con focus on oncologia, ha annunciato la sua partecipazione alla Cantor Global Healthcare Conference. L'evento è programmato per giovedì 19 settembre 2024, alle 9:45 a.m. E.T. a New York, NY.
Il Dr. David Hung, Fondatore, Presidente e Amministratore Delegato di Nuvation Bio, presenterà alla conferenza. Le parti interessate possono accedere a un webcast dal vivo della presentazione tramite il sito web delle relazioni con gli investitori dell'azienda. Per coloro che non possono partecipare dal vivo, sarà disponibile una registrazione archiviata per 90 giorni dopo l'evento.
Nuvation Bio Inc. (NYSE: NUVB), una compañía biofarmacéutica en etapa clínica avanzada con enfoque en oncología, ha anunciado su participación en la Cantor Global Healthcare Conference. El evento está programado para jueves 19 de septiembre de 2024, a las 9:45 a.m. E.T. en Nueva York, NY.
El Dr. David Hung, Fundador, Presidente y Director Ejecutivo de Nuvation Bio, presentará en la conferencia. Las partes interesadas pueden acceder a un webcast en vivo de la presentación a través del sitio web de relaciones con inversionistas de la empresa. Para aquellos que no puedan asistir en vivo, habrá una grabación archivada disponible por 90 días después del evento.
Nuvation Bio Inc. (NYSE: NUVB), 온콜로지에 중점을 둔 후기 임상 단계의 생명공학 회사가 Cantor Global Healthcare Conference에 참여한다고 발표했습니다. 이 행사는 2024년 9월 19일 목요일 오전 9:45 E.T.에 뉴욕에서 개최됩니다.
Nuvation Bio의 창립자이자 회장, CEO인 Dr. David Hung가 회의에서 발표할 예정입니다. 관심 있는 분들은 회사의 투자자 관계 웹사이트를 통해 발표의 실시간 웹캐스트에 접속할 수 있습니다. 실시간 참석이 불가능한 경우, 행사가 끝난 후 90일 동안 저장된 녹화본이 제공될 것입니다.
Nuvation Bio Inc. (NYSE: NUVB), une entreprise biopharmaceutique en phase clinique avancée axée sur l'oncologie, a annoncé sa participation à la Cantor Global Healthcare Conference. L'événement est prévu pour le jeudi 19 septembre 2024, à 9h45 E.T. à New York, NY.
Le Dr David Hung, fondateur, président et directeur général de Nuvation Bio, fera une présentation lors de la conférence. Les parties intéressées peuvent accéder à un webinaire en direct de la présentation via le site Web des relations avec les investisseurs de l'entreprise. Pour ceux qui ne peuvent pas assister en direct, un enregistrement archivé sera disponible pendant 90 jours après l'événement.
Nuvation Bio Inc. (NYSE: NUVB), ein biopharmazeutisches Unternehmen in der späten klinischen Phase mit Schwerpunkt auf Onkologie, hat seine Teilnahme an der Cantor Global Healthcare Conference bekannt gegeben. Die Veranstaltung ist für Donnerstag, den 19. September 2024, um 9:45 Uhr E.T. in New York, NY, angesetzt.
Dr. David Hung, der Gründer, Präsident und CEO von Nuvation Bio, wird auf der Konferenz präsentieren. Interessierte Parteien können über die Investor-Relations-Website des Unternehmens auf einen Live-Webcast der Präsentation zugreifen. Für diejenigen, die nicht live teilnehmen können, wird eine archivierte Aufzeichnung für 90 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuvationbio.com/investors/. An archived recording will be available for 90 days following the event.
About Nuvation Bio
Nuvation Bio is a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. Nuvation Bio’s portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909328377/en/
Nuvation Bio Investor Contact:
ir@nuvationbio.com
Nuvation Bio Media Contact:
media@nuvationbio.com
Source: Nuvation Bio
FAQ
When is Nuvation Bio (NUVB) presenting at the Cantor Global Healthcare Conference?
Who will be presenting for Nuvation Bio (NUVB) at the Cantor Global Healthcare Conference?
How can I watch Nuvation Bio's (NUVB) presentation at the Cantor Global Healthcare Conference?
How long will the recording of Nuvation Bio's (NUVB) presentation be available after the conference?
